Literature DB >> 11516112

Real-time quantitative PCR for detection of minimal residual disease before allogeneic stem cell transplantation predicts outcome in children with acute lymphoblastic leukemia.

V H van der Velden, S A Joosten, M J Willemse, E R van Wering, A W Lankester, J J van Dongen, P M Hoogerbrugge.   

Abstract

Entities:  

Mesh：

Year:  2001        PMID： 11516112     DOI： 10.1038/sj.leu.2402198

Source DB:  PubMed          Journal:  Leukemia        ISSN： 0887-6924            Impact factor:   11.528


× No keyword cloud information.
  19 in total

1.  Relationship between minimal residual disease measured by multiparametric flow cytometry prior to allogeneic hematopoietic stem cell transplantation and outcome in children with acute lymphoblastic leukemia.

Authors:  Izaskun Elorza; Carlos Palacio; Jose Luis Dapena; Laura Gallur; José Sánchez de Toledo; Cristina Díaz de Heredia
Journal:  Haematologica       Date:  2010-02-23       Impact factor: 9.941

2.  Quantitative analysis of minimal residual disease predicts relapse in children with B-lineage acute lymphoblastic leukemia in DFCI ALL Consortium Protocol 95-01.

Authors:  Jianbiao Zhou; Meredith A Goldwasser; Aihong Li; Suzanne E Dahlberg; Donna Neuberg; Hongjun Wang; Virginia Dalton; Kathryn D McBride; Stephen E Sallan; Lewis B Silverman; John G Gribben
Journal:  Blood       Date:  2007-05-07       Impact factor: 22.113

3.  Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.

Authors:  Sahra Ali; Alexandre Moreau; Daniela Melchiorri; Jorge Camarero; Filip Josephson; Odoardo Olimpier; Jonas Bergh; Dominik Karres; Kyriaki Tzogani; Christian Gisselbrecht; Francesco Pignatti
Journal:  Oncologist       Date:  2019-11-14

Review 4.  Recent advances in hematopoietic stem cell transplantation for childhood acute lymphoblastic leukemia.

Authors:  Veronica Jude; Ka Wah Chan
Journal:  Curr Hematol Malig Rep       Date:  2010-07       Impact factor: 3.952

5.  Hematopoietic Stem Cell Transplantation for Childhood Acute Lymphoblastic Leukemia and the Role of MRD: A Single Centre Experience from India.

Authors:  Divya Subburaj; Lakshman Vaidyanathan; Ramya Uppuluri; Dhaarani Jayaraman; Revathi Raj
Journal:  Indian J Hematol Blood Transfus       Date:  2017-05-20       Impact factor: 0.900

6.  Blinatumomab for Acute Lymphoblastic Leukemia: The First Bispecific T-Cell Engager Antibody to Be Approved by the EMA for Minimal Residual Disease.

Authors:  Sahra Ali; Alexandre Moreau; Daniela Melchiorri; Jorge Camarero; Filip Josephson; Odoardo Olimpier; Jonas Bergh; Dominik Karres; Kyriaki Tzogani; Christian Gisselbrecht; Francesco Pignatti
Journal:  Oncologist       Date:  2019-11-14

7.  The effect of peritransplant minimal residual disease in adults with acute lymphoblastic leukemia undergoing allogeneic hematopoietic stem cell transplantation.

Authors:  Yi Zhou; Rebecca Slack; Jeffrey L Jorgensen; Sa A Wang; Gabriela Rondon; Marcos de Lima; Elizabeth Shpall; Uday Popat; Stefan Ciurea; Amin Alousi; Muzaffar Qazilbash; Chitra Hosing; Susan O'Brien; Deborah Thomas; Hagop Kantarjian; L Jeffrey Medeiros; Richard E Champlin; Partow Kebriaei
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-01-15

Review 8.  Minimal residual disease in acute lymphoblastic leukemia.

Authors:  Dario Campana
Journal:  Semin Hematol       Date:  2009-01       Impact factor: 3.851

Review 9.  Role of minimal residual disease monitoring in adult and pediatric acute lymphoblastic leukemia.

Authors:  Dario Campana
Journal:  Hematol Oncol Clin North Am       Date:  2009-10       Impact factor: 3.722

10.  Implementation of the standard strategy for identification of Ig/TCR targets for minimal residual disease diagnostics in B-cell precursor ALL pediatric patients: Polish experience.

Authors:  Małgorzata Dawidowska; Justyna Jółkowska; Tomasz Szczepański; Katarzyna Derwich; Jacek Wachowiak; Michał Witt
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  2008-12-01       Impact factor: 4.291
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.